ZA99477B - Process for the preparation of (-)CIS-3-Hydroxy-1-Methyl-4-(2,4,6-Trimethoxyphenyl)Piperidine. - Google Patents

Process for the preparation of (-)CIS-3-Hydroxy-1-Methyl-4-(2,4,6-Trimethoxyphenyl)Piperidine.

Info

Publication number
ZA99477B
ZA99477B ZA9900477A ZA99477A ZA99477B ZA 99477 B ZA99477 B ZA 99477B ZA 9900477 A ZA9900477 A ZA 9900477A ZA 99477 A ZA99477 A ZA 99477A ZA 99477 B ZA99477 B ZA 99477B
Authority
ZA
South Africa
Prior art keywords
trimethoxyphenyl
piperidine
cis
hydroxy
methyl
Prior art date
Application number
ZA9900477A
Other languages
English (en)
Inventor
Gerhard Breipohl
Juergen Michalowsky
Original Assignee
Hoechst Marion Roussel De Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel De Gmbh filed Critical Hoechst Marion Roussel De Gmbh
Publication of ZA99477B publication Critical patent/ZA99477B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA9900477A 1998-01-23 1999-01-22 Process for the preparation of (-)CIS-3-Hydroxy-1-Methyl-4-(2,4,6-Trimethoxyphenyl)Piperidine. ZA99477B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19802449A DE19802449A1 (de) 1998-01-23 1998-01-23 Verfahren zur Herstellung von (-)cis-3-Hydroxy-1-methyl-4-(2,4,6-trimethoxypyhenyl)-piperidin

Publications (1)

Publication Number Publication Date
ZA99477B true ZA99477B (en) 1999-09-23

Family

ID=7855418

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9900477A ZA99477B (en) 1998-01-23 1999-01-22 Process for the preparation of (-)CIS-3-Hydroxy-1-Methyl-4-(2,4,6-Trimethoxyphenyl)Piperidine.

Country Status (27)

Country Link
US (1) US6225473B1 (ja)
EP (1) EP1049674B1 (ja)
JP (1) JP4585116B2 (ja)
KR (1) KR100567941B1 (ja)
CN (1) CN1137096C (ja)
AR (1) AR015218A1 (ja)
AT (1) ATE355270T1 (ja)
AU (1) AU762407B2 (ja)
BR (1) BR9814774B1 (ja)
CA (1) CA2318946C (ja)
CY (1) CY1106511T1 (ja)
CZ (1) CZ298852B6 (ja)
DE (2) DE19802449A1 (ja)
DK (1) DK1049674T3 (ja)
ES (1) ES2281943T3 (ja)
HK (1) HK1033319A1 (ja)
HU (1) HU227928B1 (ja)
IL (1) IL137422A (ja)
NO (1) NO321933B1 (ja)
NZ (1) NZ505897A (ja)
PL (1) PL190790B1 (ja)
PT (1) PT1049674E (ja)
RU (1) RU2265595C2 (ja)
SK (1) SK285883B6 (ja)
TR (1) TR200002146T2 (ja)
WO (1) WO1999037615A1 (ja)
ZA (1) ZA99477B (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6437136B2 (en) * 1998-01-23 2002-08-20 Aventis Pharma Deutschland Gmbh Process for the preparation of (−)cis-3-hydroxy-1-methyl-4-(2,4,6-trimethoxyphenyl)piperidine
DE19809649A1 (de) * 1998-03-06 1999-09-09 Hoechst Marion Roussel De Gmbh Verfahren zur enzymatischen Enantiomeren-Trennung von 3(R)- und 3(S)-Hydroxy-1-methyl-4-(2,4,6-trimethoxyphenyl)-1,2,3,6-tetrahydro-pyridin bzw. der Carbonsäureester
CA2982928A1 (en) 2015-04-20 2016-10-27 Tolero Pharmaceuticals, Inc. Predicting response to alvocidib by mitochondrial profiling
KR102608921B1 (ko) 2015-05-18 2023-12-01 스미토모 파마 온콜로지, 인크. 생체 이용률이 증가된 알보시딥 프로드러그
CN108289861B (zh) 2015-08-03 2021-11-02 大日本住友制药肿瘤公司 用于治疗癌症的组合疗法
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
WO2018119000A1 (en) 2016-12-19 2018-06-28 Tolero Pharmaceuticals, Inc. Profiling peptides and methods for sensitivity profiling
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
CN110577974B (zh) * 2019-09-10 2021-07-20 杭州澳赛诺生物科技有限公司 手性3-羟基-1,2,3,6-四氢吡啶的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN164232B (ja) * 1986-04-11 1989-02-04 Hoechst India
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
DE3836676A1 (de) * 1988-10-28 1990-05-03 Hoechst Ag Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel
US5849733A (en) * 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
US5908934A (en) * 1996-09-26 1999-06-01 Bristol-Myers Squibb Company Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs

Also Published As

Publication number Publication date
NO20003454D0 (no) 2000-07-04
JP2002501048A (ja) 2002-01-15
AR015218A1 (es) 2001-04-18
CZ298852B6 (cs) 2008-02-27
DE19802449A1 (de) 1999-07-29
PL190790B1 (pl) 2006-01-31
KR20010024867A (ko) 2001-03-26
PL342064A1 (en) 2001-05-21
EP1049674A1 (de) 2000-11-08
IL137422A (en) 2005-11-20
NO321933B1 (no) 2006-07-24
NO20003454L (no) 2000-07-04
HUP0100649A1 (hu) 2001-07-30
IL137422A0 (en) 2001-07-24
CY1106511T1 (el) 2012-01-25
ES2281943T3 (es) 2007-10-01
CA2318946A1 (en) 1999-07-29
DK1049674T3 (da) 2007-06-25
SK285883B6 (sk) 2007-10-04
HUP0100649A3 (en) 2002-12-28
CA2318946C (en) 2009-11-03
RU2265595C2 (ru) 2005-12-10
CN1137096C (zh) 2004-02-04
SK10972000A3 (sk) 2000-12-11
CN1284065A (zh) 2001-02-14
AU2513599A (en) 1999-08-09
ATE355270T1 (de) 2006-03-15
TR200002146T2 (tr) 2000-12-21
WO1999037615A1 (de) 1999-07-29
PT1049674E (pt) 2007-04-30
AU762407B2 (en) 2003-06-26
US6225473B1 (en) 2001-05-01
BR9814774B1 (pt) 2010-10-05
BR9814774A (pt) 2000-11-14
CZ20002665A3 (cs) 2001-11-14
HK1033319A1 (en) 2001-08-24
EP1049674B1 (de) 2007-02-28
KR100567941B1 (ko) 2006-04-07
JP4585116B2 (ja) 2010-11-24
HU227928B1 (en) 2012-06-28
DE59813924D1 (de) 2007-04-12
NZ505897A (en) 2003-03-28

Similar Documents

Publication Publication Date Title
PL348827A1 (en) Process for making 2,3-dihalopropanols
HUP0002105A3 (en) Method for preparing 1,1,1,3,3-pentachlorobutane
ZA99477B (en) Process for the preparation of (-)CIS-3-Hydroxy-1-Methyl-4-(2,4,6-Trimethoxyphenyl)Piperidine.
ZA200007253B (en) Process for preparing 1,4-dihydropyridine compounds.
EP1023250A4 (en) METHOD FOR PRODUCING 2,6-DIALKYLNAPHTHALINE
ZA995597B (en) Process for the preparation of nicotinic acid.
IL139023A0 (en) Process for the preparation of 2,3,5-trimethyl-p- benzoquinone
GB2343892B (en) Process for the preparation of d,l-menthol
HUP0003452A3 (en) Process for the preparation of 1-aryl-3-cyclopropyl-1,3-propanediones
IL138404A0 (en) Process for making 1,3-disubstituted -4-oxocylic ureas
ZA982255B (en) Process for the preparation of arylmalonates.
HUP9802054A3 (en) Process for producing 4,4,5,5,5-pentafluor-1-pentanol
ZA988397B (en) Process for the preparation of substituted 5,6-dihydro-2H-pyran-2-ones
IL138405A0 (en) Process for making 1,3-disubstituted-4-oxocyclic ureas
ZA200102818B (en) Process for the preparation of 4,4'-dihalogen-O-hydroxydiphenyl compounds.
IL146573A0 (en) Method for producing 2,2,4,4-tetra-substituted 1,3,5-cyclohexanetriones
HU9802105D0 (en) Process for producing 2,3,4,5-tetrafluorbenzene derivatives
IL137364A (en) Process for the preparation of 6,6-dimethylhept-1-en-4-yn-3-ol
ZA991215B (en) Process for the preparation of 1,3-disubstituted 2-nitroguanidines.
ZA991576B (en) Process for the preparation of substituted pyridines.
PL344141A1 (en) Process for preparation of 4,5-epoxymorphinan-6-oxyglucuronides
AU6086998A (en) Process for preparing 1,4-disubstituted piperidine compounds
ZA983781B (en) Process for the preparation of 1,1,1,3,3-pentachlorobutane.
ZA984814B (en) Process for the preparation of Chiral 3,4-dehydropro-lines.
HK1062678A1 (en) Process for preparing 8-cyclopentyl-6-ethyl-3-ÄsubstitutedÜ-5,8-dihydro-4H 7,8-pentaaza-as-indacenesand intermediates useful therein